New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Although the role of metabolic syndrome (MS) and a high fat diet in prostate cancer (PCa) risk is still a matter of intense debate, it is becoming increasingly clear that obesity can cause perturbations in metabolic pathways that contribute to the pathogenesis and progression of PCa. Moreover, prostate epithelial cells per se undergo a series of metabolic changes, including an increase in de novo lipogenesis, during the process of tumor formation. These metabolic alterations, at both the cellular and organismal levels, are intertwined with genetic aberrations necessary for neoplastic transformation. Thus, altered metabolism is currently subject to intense research efforts and might provide preventative and therapeutic opportunities, as well as a platform for biomarker development. In this article, we review evidence that the metabolic sensor 5′-AMP-activated protein kinase (AMPK), which physiologically integrates nutritional and hormonal signals and regulates cell survival and growth-related metabolic pathways to preserve intracellular ATP levels, represents a link between energy homeostasis and cancer. Thus, when AMPK is not activated, as in the setting of MS and obesity, systemic metabolic alterations permissive to the development of PCa are allowed to proceed unchecked. Hence, the use of AMPK activators and inhibitors of key lipogenic enzymes may represent a promising therapeutic strategy for PCa. Clin Cancer Res; 16(13); 3322–8. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“ACC, FASN, and HMG-CoA reductase are responsible for the synthesis of malonyl-CoA, the saturated FA palmitate, and mevalonate (the precursor of cholesterol), respectively, and their role in the pathogenesis and progression of PCa is well established (49, 50).”
BackgroundMetformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Recent evidence indicates that: (a) patients with diabetes under treatment with metformin show a reduced cancer incidence (32) and cancer-related mortality compared with patients exposed to sulfonylureas or insulin (33); (b) metformin use is associated with a 44% risk reduction in PCa cases compared with controls in C…”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 1×
“Metformin's indirect effect on tumor proliferation can be explained via inhibition of hepatic gluconeogenesis and increased glucose uptake in skeletal muscle, thereby decreasing circulating glucose, insulin, and IGF-1 levels, and resultant signaling flux through the insulin/IGF-1 pathway (42).”
BackgroundThe LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943 · cited 1×
“Finally, it induces cell cycle arrest or apoptosis through phosphorylation of p53 and FOXO3a (59).”
BackgroundLKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115 · cited 1×
“These human studies are further supported by studies in vitro and in xenograft models, showing its antitumor activity on PCa cells (18, 36), and by the exciting discovery that metformin is able to selectively kill cancer stem cells from four genetically distinct breast cancer lines (37).”
BackgroundOrchard, T. J., Temprosa, M., Goldberg, R., Haffner, S., Ratner, R., Marcovina, S., Fowler, S., & for the Diabetes Prevention Program Research Group (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-8-200504190-00009 · Cited by 948 · cited 1×
“It has been shown to prevent or delay the onset of MS (31).”
BackgroundBowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Cited by
AMPK activators: mechanisms of action and physiological activities
Kim, J., Yang, G., Kim, Y., Kim, J., & Ha, J. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.16 · Cited by 817
CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential
Schlaepfer, I. R., & Joshi, M. (2020) · Endocrinology · doi:10.1210/endocr/bqz046 · Cited by 732
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer
Watt, M. J., Clark, A. K., Selth, L. A., Haynes, V. R., Lister, N., Rebello, R., Porter, L. H., Niranjan, B., Whitby, S. T., Lo, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5758 · Cited by 320
The fat side of prostate cancer
Zadra, G., Photopoulos, C., & Loda, M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.03.010 · Cited by 291
Self-citationMetformin as an Anticancer Agent
Vancura, A., Bu, P., Bhagwat, M., Zeng, J., & Vancurova, I. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.006 · Cited by 274
Metadata
- Authors
- Zadra, G., Priolo, C., Patnaik, A., & Loda, M.
- Venue
- Clinical Cancer Research
- Published
- 2010-06-30
- Volume
- 16
- Issue
- 13
- Pages
- 3322-3328
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2148669892
- Cited by
- 67
- References
- 18
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1955
- The paper
- Zadra, G., Priolo, C., Patnaik, A., & Loda, M. (2010). New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1955
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.